The Changing Face of cN0M0 Prostate Cancer Being Found With pN+ After Surgery in the Contemporary Era: Results of an International European Survey on Disease Management.


Journal

Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955

Informations de publication

Date de publication:
06 2023
Historique:
received: 26 09 2022
revised: 09 11 2022
accepted: 14 11 2022
medline: 29 5 2023
pubmed: 8 1 2023
entrez: 7 1 2023
Statut: ppublish

Résumé

The urological community's opinion over the management of men being found with pathologically positive nodes (pN+) following radical prostatectomy (RP) performed with curative intent after preoperative negative conventional staging (cN0M0) has never been assessed. This remains crucial, especially considering the advent of novel imaging modalities. Our aim was to investigate the current opinion on management of pN+ cN0M0 prostate cancer (PCa) in the European urological community. Following validation, a 31-item survey, complying with the Cherries checklist, was distributed using a web link from December 2021 to April 2022 to 10 urological societies mailing list. Social media (Twitter, Facebook) were also used. We received 253 replies. The majority were Urologists (96.8%), younger than 60 (90.5%); 5.2% did not have access to PET-scans; 78.9% believed pN+ is a multifaceted category; 10-years CSS was marked as 71 to 95% by 17.5%. Gold standard management was stated not being ADT by 80.8% and being RT±ADT by 52.3%. Early sRT±ADT was considered an option vs. aRT±ADT by 72.4%. In case of BCR 71% would perform and decide management based on PSMA-PET whilst 3.7% would not perform PSMA-PET. pN+ management is still unclear for 77.1%. On multivariate analysis PSMA-PET availability related to a lower and higher likelihood of considering aRT±ADT as standard and of considering early salvage versus aRT respectively (P < .05). The Urological community has an acceptable awareness of pN+ disease and management, although it may overestimate disease aggressiveness. The majority consider pN+ PCa as a multifaceted category and rely on a risk-adapted approach. Expectant compared to immediate upfront management and new imaging modalities are increasingly considered.

Identifiants

pubmed: 36609130
pii: S1558-7673(22)00246-4
doi: 10.1016/j.clgc.2022.11.012
pii:
doi:

Substances chimiques

Gallium Radioisotopes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

416.e1-416.e10

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Auteurs

Matteo Sacco (M)

Department of Urology, San Giovanni Battista Hospital, University of Torino, Torino, Italy.

Giorgio Gandaglia (G)

Unit of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Kirsti Aas (K)

Department of Surgery, Vestre Viken Hospital Trust, Bærum Hospital, Drammen, Norway.

Francesco Ceci (F)

Division of Nuclear Medicine, IEO European Institute of Oncology, Milan, Italy.

Peter Chiu (P)

SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.

Christian D Fankhauser (CD)

Department of Urology, University Hospital Zürich, University of Zürich, Zurich, Switzerland.

Georges Fournier (G)

AFU, Association Francaise d'Urologie.

Isabel Heiddeger (I)

Department of Urology, Medical University Innsbruck, Innsbruck, Austria.

Veeru Kasivisvanathan (V)

Division of Surgery and Interventional Science, University College London, London, UK.

Claudia Kesch (C)

Department of Urology, University Hospital Essen, Essen, Germany.

Martina Maggi (M)

Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy.

Alberto Martini (A)

Unit of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Jonathan Olivier (J)

Department of Urology, Lille University Hospital, Lille, France.

Guillaume Ploussard (G)

AFU, Association Francaise d'Urologie.

Felix Preisser (F)

Department of Urology, University Hospital Frankfurt, Frankfurt, Germany.

Ignacio Puche-Sanz (I)

Department of Urology, Bio-Health Research Institute, Hospital Universitario Virgen de las Nieves, University of Granada, Granada, Spain.

Pawel Rajwa (P)

Department of Urology, Medical University of Silesia, Zabrze, Poland.

Timo Soeterik (T)

Department of Urology, St. Antonius Hospital, Utrecht, The Netherlands.

Constance Thibault (C)

Department of Medical Oncology, European Georges Pompidou Hospital, Assistance Publique des Hôpitaux de Paris, Paris Descartes University, Paris, France.

Massimo Valerio (M)

Department of Urology, CHUV Lausanne, Lausanne, Switzerland.

Roderick C N van den Bergh (RCN)

Department of Urology, St. Antonius Hospital, Utrecht, The Netherlands.

Fabio Zattoni (F)

Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.

Juan Gómez Rivas (JG)

Department of Urology, Hospital Clínico San Carlos, Madrid, Spain.

Marco Moschini (M)

Unit of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Silke Gillessen (S)

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland.

Alberto Bossi (A)

Department of Radiotherapy, Gustave Roussy Cancer Institute, Villejuif, France.

Paolo Gontero (P)

Department of Urology, San Giovanni Battista Hospital, University of Torino, Torino, Italy.

Giancarlo Marra (G)

Department of Urology, San Giovanni Battista Hospital, University of Torino, Torino, Italy. Electronic address: drgiancarlomarra@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH